Handa Pharmaceuticals, Inc. Stock

Equities

6620

TW0006620008

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
108.5 TWD -.--% Intraday chart for Handa Pharmaceuticals, Inc. -20.80% -40.87%
Sales 2024 * 2.55B 78.56M Sales 2025 * - Capitalization 15.31B 472M
Net income 2024 * 2.08B 64.08M Net income 2025 * - EV / Sales 2024 * 4.74 x
Net cash position 2024 * 3.22B 99.16M Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
6.79 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
1 week-20.80%
1 month-12.85%
3 months-37.82%
6 months-35.61%
Current year-40.87%
More quotes
1 week
97.90
Extreme 97.9
128.50
1 month
97.90
Extreme 97.9
145.50
Current year
97.90
Extreme 97.9
196.00
1 year
97.90
Extreme 97.9
206.00
3 years
26.50
Extreme 26.5
221.00
5 years
15.45
Extreme 15.45
221.00
10 years
15.45
Extreme 15.45
221.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 05-10-31
Director of Finance/CFO - -
Director/Board Member - 16-03-07
Members of the board TitleAgeSince
Director/Board Member - 19-06-27
Director/Board Member - 17-09-27
Director/Board Member - 17-09-27
More insiders
Date Price Change Volume
24-05-31 108.5 -.--% 853,054
24-05-30 108.5 -3.12% 1,339,999
24-05-29 112 -4.68% 1,678,218
24-05-28 117.5 -0.84% 1,107,946
24-05-27 118.5 -13.50% 4,521,291

End-of-day quote Taipei Exchange, May 30, 2024

More quotes
Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
108.5 TWD
Average target price
200 TWD
Spread / Average Target
+84.33%
Consensus

Annual profits - Rate of surprise